Mathias Oelke

Mathias Oelke is an accomplished Ph.D. scientist and business partner with 20 years of experience in cancer immunotherapy and deep expertise in immunology, particularly in T-cell biology.

He currently holds the position of Senior Vice President and Head of Preclinical Immunotherapy and Platform Development at NexImmune, Inc., while also serving as an adjunct Professor at JHU in Baltimore.

Dr. Oelke is known for developing the AIM platform technology, based on artificial antigen presenting cells (aAPC’s), which has broad applications in immunotherapy, adoptive cellular therapies, target discovery, and cellular manufacturing.

He co-founded NexImmune, a biotech startup that originated from JHU and is now situated in Gaithersburg, with Jon Schneck and Ken Carter, showcasing his entrepreneurial spirit.

His contributions include successful tech transfer, establishing the NexImmune lab, talent identification and management, and advancing technology to GMP development.

Dr. Oelke's expertise lies in cellular immunology and T-cell research, particularly in the innovative 'artificial Antigen Presenting Cell' technology.

He has an extensive network of collaborations in the USA and Europe, holding ownership of over 15 patents related to aAPC technology and having pending patent applications in the field of cancer immunotherapy.